Search Results

Purdue Pharma L.P. (“Purdue”) announced today that the Company has awarded an investigator-initiated research (IIR) grant to a team of researchers at The University of New Mexico (UNM) for the evaluation of nalmefene hydrochloride (HCl) injection 2mg/2mL (1mg/1mL) in the emergency department setting.

Sumitomo Pharma Canada, Inc., announced that ORGOVYX®, an oral gonadotropin-releasing hormone receptor antagonist, is now available for prescription in Canada for the treatment of adult patients with advanced prostate cancer.

Mitsubishi Tanabe Pharma Canada a subsidiary of Mitsubishi Tanabe Pharma America, Inc., announced that RADICAVA® Oral Suspension for the treatment of amyotrophic lateral sclerosis, a rapidly progressive, neurodegenerative disease1, is now reimbursed by Veterans Affairs Canada and Indigenous Services Canada via the Non-Insured Health Benefits Program.

BioSyent Inc. is pleased to announce that its wholly-owned subsidiary, BioSyent Pharma Inc., has entered into an agreement with a European partner for an exclusive license to register, market, sell and distribute a new endocrinology product in Canada.

China is adapting its Life Sciences policy to bolster innovation and data transparency. Big Pharma is taking note.

Nora Pharma, a Canadian pharmaceutical company, has received approval for its first Biosimilar product.

Sumitomo Pharma Canada, Inc. and Pfizer Canada today announced that Health Canada has granted a Notice of Compliance (NOC) for MYFEMBREE (Relugolix, estradiol and norethindrone acetate tablets) for the management of moderate to severe pain associated with endometriosis in pre-menopausal women on October 17, 2023.